REG - Hikma Pharmaceutical - Total Voting Rights

Hikma PharmaceuticalsAnnouncement

01/07/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220701:nRSA0202Ra&default-theme=true

RNS Number : 0202R  Hikma Pharmaceuticals Plc  01 July 2022

 

Hikma Pharmaceuticals PLC

(the Company)

Total Voting Rights and Capital

 

LONDON, 1 July 2022 - In accordance with section 5.6.1 of the UK Financial
Conduct Authority's Disclosure Guidance and Transparency Rules (the 'Rules'),
Hikma Pharmaceuticals PLC

(LEI: 549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the market
of the following:

 

As at 30 June 2022, the issued share capital of the Company comprised of
220,108,323 Ordinary Shares of 10 pence each ('Shares') with voting rights.
This figure excludes 12,833,233 Shares held in treasury, which do not have
voting rights.

 

The figure of 220,108,323 may be used by shareholders (and others with
notification obligations) as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the Rules.

 

 

 

 

- ENDS -

 

Enquiries

 

 Hikma Pharmaceuticals PLC

 Hussein Arkhagha                      +44 20 7399 2785

 Chief Counsel and Company Secretary

 

About Hikma

Hikma helps put better health within reach every day for millions of people in
more than 50 countries around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the people who
need them. Headquartered in the UK, we are a global company with a local
presence across the United States (US), the Middle East and North Africa
(MENA) and Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform people's lives.
We're committed to our customers, and the people they care for, and by
thinking creatively and acting practically, we provide them with a broad range
of branded and non-branded generic medicines. Together, our 8,600 colleagues
are helping to shape a healthier world that enriches all our communities. We
are a leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the world. For
more information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Cmellisa%40hikma.uk.com%7C997d2fa3727b41845d4308d7ecef5a5f%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C0%7C637238385059390461&sdata=JoY1dcOqWcUS12nfDFqq49wlYgBsw3%2BZFmrlDQ4QNI0%3D&reserved=0)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREANXFESAAEEA